Wed, Mar 4, 2015, 3:36 PM EST - U.S. Markets close in 24 mins.

Recent

% | $
Quotes you view appear here for quick access.

Arrayit Corporation Message Board

  • b2btrillionsayear b2btrillionsayear Apr 16, 2011 8:41 AM Flag

    Ovarian Cancer Test (OvaDx) - Parkinson's mention in 10q - SOUNDS FANTASTIC

    Strategic Relationships and Licensing Arrangements

    Arrayit Corporation and Wayne State University recently completed Task 2 of a sponsored research agreement to study ovarian cancer. This research produced three new proteomic markers that may provide additional sensitivity and specificity for the OvaDx test.

    The OvaDx test for diagnostics use will be marketed and sold upon FDA approval by the company’s majority owned subsidiary, Arrayit Diagnostics, Inc. Arrayit Corporation and Arrayit Diagnostics, Inc are exploring strategic partnership opportunities with corporations that have a strong customer base, and a significant sales and marketing presence in the diagnostics industry worldwide.

    Arrayit Corporation announced the launch of OvaDx for research use only at the American Association for Cancer Research Meeting in Orlando, Florida on April 2, 2011. It is a sophisticated microarray-based test that measures the activation of the immune system in response to early stage ovarian tumor cell development. Research studies with OvaDx indicate high sensitivity and specificity for all types and stages of ovarian cancer. Serum is applied to the OvaDx microarray to allow binding between proteomic biomarkers in the sample and capture agents on the microarray. The microarray is washed and scanned to produce a digital readout for each serum sample, and the data are quantified and analyzed in software to generate the test results. Pricing for the first 1,000 tests is set at USD 650 per sample. The company's OvaDx Pre-Symptomatic Ovarian Cancer Screening Test is marketed "for research purposes only" in advance of FDA approval, and is not to be used for any patient management purposes prior to FDA approval. Researchers can use the test to analyze different tumor types and stages, the effectiveness of chemotherapies, biomarker profiles in breast cancer and other epithelial cancers, studies of benign gynecological conditions, the effectiveness of ovarian cancer drugs for treatment and prevention, and to benchmark existing tests including CA-125, OVA1, and transvaginal ultrasound.

    BioSystems International (BSI) is producing antibodies of blood plasma, taken from human sources, for which Arrayit has developed a PlasmaScan™ microarray that potentially has the capability to identify predictors and biomarkers for such difficult to diagnose diseases as Parkinson’s disease and Alzheimer’s disease, among others. Once these biomarkers are identified, a diagnostic slide could then be developed for broad use across the healthcare industry. Arrayit will also benefit from licensing of these antibodies for such downstream applications.

    Arrayit has an ongoing collaboration with the Parkinson’s Institute to test known Parkinson’s Disease (PD) patients’ blood to identify biomarkers for Parkinson’s Disease from the human plasma proteome microarray marketed as PlasmaScan. Arrayit is also using the H25K Whole Human Genome Microarray to examine PD samples and has identified the world’s first functional mRNA biomarkers for Parkinson’s Disease. An expanded patient study will be used to further validate the PD biomarkers. Arrayit is also working with Stanford University to test known Alzheimer’s patients’ blood to identify biomarkers for Alzheimer’s Disease using PlasmaScan and other tools.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARYC.PK
0.15-0.01(-6.13%)Oct 30 2:09 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.